These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

881 related items for PubMed ID: 18489991

  • 1. Similar risks for chronic kidney disease in long-term survivors of myeloablative and reduced-intensity allogeneic hematopoietic cell transplantation.
    Al-Hazzouri A, Cao Q, Burns LJ, Weisdorf DJ, Majhail NS.
    Biol Blood Marrow Transplant; 2008 Jun; 14(6):658-63. PubMed ID: 18489991
    [Abstract] [Full Text] [Related]

  • 2. Early and late neurological complications after reduced-intensity conditioning allogeneic stem cell transplantation.
    Barba P, Piñana JL, Valcárcel D, Querol L, Martino R, Sureda A, Briones J, Delgado J, Brunet S, Sierra J.
    Biol Blood Marrow Transplant; 2009 Nov; 15(11):1439-46. PubMed ID: 19822304
    [Abstract] [Full Text] [Related]

  • 3. Similar risks for hypothyroidism after allogeneic hematopoietic cell transplantation using TBI-based myeloablative and reduced-intensity conditioning regimens.
    Al-Hazzouri A, Cao Q, Burns LJ, Weisdorf DJ, Majhail NS.
    Bone Marrow Transplant; 2009 Jun; 43(12):949-51. PubMed ID: 19104492
    [Abstract] [Full Text] [Related]

  • 4. Chronic kidney disease in long-term survivors of myeloablative allogeneic haematopoietic cell transplantation: prevalence and risk factors.
    Ando M, Ohashi K, Akiyama H, Sakamaki H, Morito T, Tsuchiya K, Nitta K.
    Nephrol Dial Transplant; 2010 Jan; 25(1):278-82. PubMed ID: 19762604
    [Abstract] [Full Text] [Related]

  • 5. Chronic kidney dysfunction in patients alive without relapse 2 years after allogeneic hematopoietic stem cell transplantation.
    Abboud I, Porcher R, Robin M, de Latour RP, Glotz D, Socié G, Peraldi MN.
    Biol Blood Marrow Transplant; 2009 Oct; 15(10):1251-7. PubMed ID: 19747632
    [Abstract] [Full Text] [Related]

  • 6. Influence of the intensity of the conditioning regimen on the characteristics of acute and chronic graft-versus-host disease after allogeneic transplantation.
    Pérez-Simón JA, Díez-Campelo M, Martino R, Brunet S, Urbano A, Caballero MD, de León A, Valcárcel D, Carreras E, del Cañizo MC, López-Fidalgo J, Sierra J, San Miguel JF.
    Br J Haematol; 2005 Aug; 130(3):394-403. PubMed ID: 16042689
    [Abstract] [Full Text] [Related]

  • 7. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
    Petersen SL.
    Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
    [Abstract] [Full Text] [Related]

  • 8. Hypertension and diabetes mellitus in adult and pediatric survivors of allogeneic hematopoietic cell transplantation.
    Majhail NS, Challa TR, Mulrooney DA, Baker KS, Burns LJ.
    Biol Blood Marrow Transplant; 2009 Sep; 15(9):1100-7. PubMed ID: 19660723
    [Abstract] [Full Text] [Related]

  • 9. Regimen-related mucosal injury of the gut increased the incidence of CMV disease after allogeneic bone marrow transplantation.
    Shigematsu A, Yasumoto A, Yamamoto S, Sugita J, Kondo T, Onozawa M, Kahata K, Endo T, Ota S, Sato N, Takahata M, Okada K, Tanaka J, Hashino S, Nishio M, Koike T, Asaka M, Imamura M.
    Biol Blood Marrow Transplant; 2009 Jun; 15(6):679-85. PubMed ID: 19450752
    [Abstract] [Full Text] [Related]

  • 10. Conventional versus reduced-intensity conditioning regimen for allogeneic stem cell transplantation in patients with hematological malignancies.
    Valcárcel D, Martino R, Sureda A, Canals C, Altés A, Briones J, Sanz MA, Parody R, Constans M, Villela SL, Brunet S, Sierra J.
    Eur J Haematol; 2005 Feb; 74(2):144-51. PubMed ID: 15654906
    [Abstract] [Full Text] [Related]

  • 11. Sustained remissions of high-risk acute myeloid leukemia and myelodysplastic syndrome after reduced-intensity conditioning allogeneic hematopoietic transplantation: chronic graft-versus-host disease is the strongest factor improving survival.
    Valcárcel D, Martino R, Caballero D, Martin J, Ferra C, Nieto JB, Sampol A, Bernal MT, Piñana JL, Vazquez L, Ribera JM, Besalduch J, Moraleda JM, Carrera D, Brunet MS, Perez-Simón JA, Sierra J.
    J Clin Oncol; 2008 Feb 01; 26(4):577-84. PubMed ID: 18086801
    [Abstract] [Full Text] [Related]

  • 12. Chronic kidney disease after myeloablative allogeneic hematopoietic stem cell transplantation.
    Kersting S, Hené RJ, Koomans HA, Verdonck LF.
    Biol Blood Marrow Transplant; 2007 Oct 01; 13(10):1169-75. PubMed ID: 17889353
    [Abstract] [Full Text] [Related]

  • 13. Allogeneic stem cell transplantation for adults with myelodysplastic syndromes: importance of pretransplant disease burden.
    Warlick ED, Cioc A, Defor T, Dolan M, Weisdorf D.
    Biol Blood Marrow Transplant; 2009 Jan 01; 15(1):30-8. PubMed ID: 19135940
    [Abstract] [Full Text] [Related]

  • 14. Outcome following Reduced-Intensity Allogeneic Stem Cell Transplantation (RIC AlloSCT) for relapsed and refractory mantle cell lymphoma (MCL): a study of the British Society for Blood and Marrow Transplantation.
    Cook G, Smith GM, Kirkland K, Lee J, Pearce R, Thomson K, Morris E, Orchard K, Rule S, Russell N, Craddock C, Marks DI, Clinical Trials Committee (CTC) of the British Society for Blood and Marrow Transplantation (BSBMT).
    Biol Blood Marrow Transplant; 2010 Oct 01; 16(10):1419-27. PubMed ID: 20399879
    [Abstract] [Full Text] [Related]

  • 15. Fludarabine vs cladribine plus busulfan and low-dose TBI as reduced intensity conditioning for allogeneic hematopoietic stem cell transplantation: a prospective randomized trial.
    Markova M, Barker JN, Miller JS, Arora M, Wagner JE, Burns LJ, MacMillan ML, Douek D, DeFor T, Tan Y, Repka T, Blazar BR, Weisdorf DJ.
    Bone Marrow Transplant; 2007 Feb 01; 39(4):193-9. PubMed ID: 17220905
    [Abstract] [Full Text] [Related]

  • 16. Comparison of two pretransplant predictive models and a flexible HCT-CI using different cut off points to determine low-, intermediate-, and high-risk groups: the flexible HCT-CI Is the best predictor of NRM and OS in a population of patients undergoing allo-RIC.
    Barba P, Piñana JL, Martino R, Valcárcel D, Amorós A, Sureda A, Briones J, Delgado J, Brunet S, Sierra J.
    Biol Blood Marrow Transplant; 2010 Mar 01; 16(3):413-20. PubMed ID: 19922807
    [Abstract] [Full Text] [Related]

  • 17. Alveolar hemorrhage following allogeneic hematopoietic cell transplantation using reduced-intensity conditioning.
    Majhail NS, Parks K, Defor TE, Weisdorf DJ.
    Bone Marrow Transplant; 2006 Dec 01; 38(11):765-8. PubMed ID: 17028622
    [Abstract] [Full Text] [Related]

  • 18. Incidence of Viral and fungal infections following busulfan-based reduced-intensity versus myeloablative conditioning in pediatric allogeneic stem cell transplantation recipients.
    Satwani P, Baldinger L, Freedman J, Jacobson JS, Guerra J, van de Ven C, Morris E, Garvin J, George D, Bradley MB, Bhatia M, Tallamy B, Schwartz J, Jin Z, Cairo MS.
    Biol Blood Marrow Transplant; 2009 Dec 01; 15(12):1587-95. PubMed ID: 19896083
    [Abstract] [Full Text] [Related]

  • 19. Risk factor analysis for thrombotic microangiopathy after reduced-intensity or myeloablative allogeneic hematopoietic stem cell transplantation.
    Nakamae H, Yamane T, Hasegawa T, Nakamae M, Terada Y, Hagihara K, Ohta K, Hino M.
    Am J Hematol; 2006 Jul 01; 81(7):525-31. PubMed ID: 16755559
    [Abstract] [Full Text] [Related]

  • 20. Sequential intensified conditioning and tapering of prophylactic immunosuppressants for graft-versus-host disease in allogeneic hematopoietic stem cell transplantation for refractory leukemia.
    Liu QF, Fan ZP, Zhang Y, Jiang ZJ, Wang CY, Xu D, Sun J, Xiao Y, Tan H.
    Biol Blood Marrow Transplant; 2009 Nov 01; 15(11):1376-85. PubMed ID: 19822296
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 45.